Examining the latest strategies, trends, and outcomes in respiratory education to drive measurable improvements. In respiratory medicine, where disease burden continues to rise globally, the role of effective medical education has never been more critical. But how well does respiratory-focused education translate into meaningful learning outcomes? At nuaxia , we analysed behavioural data from respiratory education activities to understand how learning interventions influence knowledge and competence among healthcare professionals. Using advanced analytical techniques, nuaxia assessed changes in learner performance before and after respiratory education initiatives. By examining patterns in engagement, knowledge acquisition and competence development, this analysis offers clear, objective insights into what works and where respiratory education delivers the greatest impact. Key Findings at a Glance 93% of Participants Improved Their Scores The vast majority of participants attained significant gains in knowledge and competence, highlighting the strong learning value embedded in our CME activities. 67% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 67% improved 31% remained stable Only 2% saw a decrease This demonstrates how targeted education engages HCPs at their current level and supports meaningful professional growth. 46% Achieved the Top Score After Medical Education Activity Perhaps most impressively, nearly half of all participants reached the top performance group, indicating that CME activities are not only raising the bar but also helping HCPs reach it. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (50.1%) or Average (38.6%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the Top (45.6%) or High (41.2%) categories. This demonstrates that high-quality medical education not only teaches but also empowers HCPs to apply what they learn. Why These Results Matter  In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change These improvements benefit HCPs and contribute to better patient outcomes worldwide. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter.   Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies  for the Medical Education sector   Contact us on: support@nuaxia.com

In the fast-evolving world of healthcare, continuous medical education (CME) is vital. But how effective is it really? At nuaxia, we analysed tens of thousands of behavioural data points across over 350 global medical education activities, and the results are clear: high-quality education is making a measurable difference. The Power of Data in Understanding Medical Education Outcomes Using advanced data science techniques, including silhouette scoring and participant clustering, nuaxia evaluated the knowledge and competence changes amongst healthcare professionals (HCPs) before and after medical education interventions. With a large dataset spanning 170 specialisms in over 50 countries, this analysis provides robust, objective evidence of educational impact. Key Findings at a Glance 94% of Participants Improved Their Scores Nearly all HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 74% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 74% improved 23% remained stable Only 3% saw a decrease This shift underlines how well-structured education meets HCPs where they are and helps them grow, regardless of the starting point. 44% Achieved the Top Score After Medical Education Activity Perhaps most impressively, nearly half of all participants reached the top performance group, indicating that CME activities are not only raising the bar but also helping HCPs reach it. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (45.3%) or High (41.1%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (42.9%) or Top (43.5%) categories. This shows that impactful medical education doesn’t just inform - it transforms. Why These Results Matter  In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change This benefits not only HCPs but ultimately improves patient outcomes on a global scale. Our Methodology The analysis was based on: 350+ educational activities 10 therapeutic areas 170+ medical specialties 50+ countries Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter.   Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector   Contact us on: support@nuaxia.com

nuaxia is now able to offer its HCP and Patient community members over 600 different reward options globally covering over 200 countries and territories and 30 currencies. Uniquely, nuaxia specialises in educational and scientific studies that are learning opportunities for its members. These surveys provide nuaxia network members the opportunity to earn honoraria. Previously, members have chosen between Visa and Mastercard reward codes, amazon gift vouchers or charitable donations. nuaxia is delighted to be able to expand the choices available to members on how they can spend their rewards. Depending on the country that they are based in, members can now choose new options from well-known brands including major stores, restaurants, travel and hotel providers and entertainment venues. Peter Chopra, nuaxia’s CEO comments: “Our research work is focused on educational and scientific studies that are learning opportunities for our members. These surveys provide our nuaxia network members the opportunity to earn honoraria. We are delighted to be able to expand the choices available to members on how they can spend their rewards.”

nuaxia, a healthcare information technology platform announces that it has identified and formed a new Key Opinion Leader (“KOL”) network that extends to over 200 countries and territories and over 436,000 members. Qualification as a KOL is as a defined specialist physician who has published 3 or more research papers. The top 12 therapy areas are outlined below: Between them, our KOL Community has published over 3.6 million papers: Peter Chopra, nuaxia’s CEO comments: “We are really excited by the progress we have made in gathering such an extensive library of medical data and bringing such a powerful group of validated KOL’s together to form one of the world’s largest KOL networks.”

nuaxia announces that it has expanded its membership to over 3.2 million healthcare professionals in over 200 countries and territories. nuaxia’s HCP community is now one of the largest HCP communities in the world. Peter Chopra, nuaxia’s CEO comments: “When we officially launched nuaxia in 2017, we had already pulled together a community of HCP’s numbering 1 million based in the US and the 5 big markets in Europe. After 4 years of hard work building our knowledge, reach and reputation, it is enormously exciting to have transformed our network of HCP’s into a truly global professional network of 3.2 million individuals.”

As every business leader knows, you measure what you care about! The problems with the UK government’s headline figure for deaths of COVID-19 positive people in hospitals have been highlighted for several weeks. But, as the UK passed the 20k target figure for deaths in hospitals over the weekend, a Financial Times analysis suggests that the real figure could be more than double. Due to the issues on the timeliness and accuracy of UK Govt data, the FT made their estimates based on the excess of expected deaths using the “all cause excess mortality” figures. So, if we would be “doing well to keep UK deaths under 20k” and deaths are now > 20k or >40k, the conclusion we are naturally drawing is that “we are not doing well”. There is a great deal of public anger and frustration at the moment. Most of that is due to circumstances beyond anyone’s control. But we are in control of some things: complete, accurate and timely data is one thing we can and should have fixed. What might have been good enough for business as usual is not good enough with the nation in crisis. The UK Govt needs to bring in the right external resources to support it in solving the current data issues. The problem is that this issue has generated many unintended associations in the public’s perception of how they are handling the crisis and it may be too late to recover the loss of confidence and trust that it needs as it tries to lead the country to a “new normal”.

Research from Carnegie Mellon University suggests 46% of Twitter accounts talking about Coronavirus are BOTS. Researchers deployed a “bot hunter” to analyse things like the no of followers, topics tweeted, frequency of tweeting, language, types of accounts they retweet, and their mentions network. They identified more than 100 false narratives which they divided into 6 categories: cures/preventative measures, weaponization of the virus, emergency responses, the nature of the virus, self-diagnosis methods and feel-good stories. The largest category targeted by BOTS was in cures/preventative measures and this category was the most likely to become international. Example of false narratives include: Corona beer cures COVID-19 Drinking bleach cures COVID-19 5G towers cause COVID-19 US developed SARS-COV-2 as a bioweapon In most cases, the agenda is to sow distrust for political or monetary gain. It may be that video blogs (where you can see the actual person) end up being the only sure authentic form of social media communication.

As the UK passes 20k COVID-19 positive deaths, why is the impact of the SARS-CoV-2 so different in Germany compared to the UK? The UK is a genuine centre of excellence for infectious diseases and had made relatively good preparations for such an event. So, where might it have gone so wrong? Real-world decision-making. The UK has not adapted effectively when (most) things have not gone to plan (e.g. assumptions about the incubation period). Lost February. The UK government “spun their wheels” in February whilst Germany got ready. Measure what you care about. Germany invested in testing and contact tracing. The UK, even now, is disorganised. Stepping up. UK politicians, civil servants, hospital administrators and academic advisers have not had the right skillsets for this crisis (as Tony Blair has recently pointed out) and they have lacked the wisdom and humility to bring in the right resource. So, what about France/Italy (very similar story to UK) and Spain (worst of big 5)? Are South Europeans too sociable? Intuitively, the reasons for a difference don’t seem to add up to the size of the difference. What else might be at play? Any money on a genetic/epidemiological explanation too?

What’s going on in South East Asia? Absolutely without a doubt, there are issues with stated numbers in most countries. At the same time, we are not hearing about large scale unreported infections and deaths in a region that is both densely populated region and with many countries having fairly basic healthcare systems. And this is from a region adjacent to China. China: Population: 1,435m, reported cases: 83,885, deaths 4,636 Original epicentre 2.2 x larger than South East Asia There have been quite a few theories put forward, including some interesting research linking by the New York Institute of Technology (NYIT): "We found that countries without universal policies of BCG vaccination, such as Italy, the Netherlands, and the United States, have been more severely affected compared to countries with universal and long-standing BCG policies” as typically enforced in Asia. We are also seeing quite similar scenarios in highly developed North Asia and Japan: South Korea: Population: 52m, reported cases: 10,708 deaths 240 Japan: Population: 127m, reported cases: 12,368 deaths 328 No answers! Let’s hope this is being properly investigated; with international co-operation somewhat patchy, just not sure who is doing it...

Background: Remdesivir was developed as a (“failed”) treatment for Ebola Granted “compassionate use” status in the US for treatment of severe COVID-19 Gilead forced to withdraw FDA “orphan drug” status as a treatment for COVID-19 Chinese clinical trial the first to report Chinese clinical trial: n= 237 patients: 158 administered the drug to 158; 79 received a placebo Case for Prosecution: After a month, 13.9% of the patients taking the drug had died compared to 12.8% of those receiving the placebo. The trial was stopped early because of side-effects. Draft report states "Remdesivir was not associated with clinical or virological benefits” Case for Defence: Patients allowed to start up to 12 days after symptoms 1st appeared. Some evidence to suggest better outcomes if treatment started earlier The trial was terminated early due to low enrollment The report was draft and has since been withdrawn by WHO Verdict: We will know more soon. 2 phase 3 studies in progress NIAID is running a study Study on 2 regimens for moderate COVID-19 >1,700 people on a compassionate use Drug available to studies run by other sponsors.

Herd immunity is an epidemiological concept that describes the state where enough people are sufficiently immune to a disease that the infection will not spread within that group (e.g. for the MMR vaccination, that means 92-95% of the population needs to be vaccinated). What if we don’t have a vaccine? A further theory has been raised that if enough people (60%+) get COVID-19, recover and develop immunity, then then we will achieve natural herd immunity. Sounds good, what’s the catch? - Time. Any strategy would need to be tightly controlled or else 1% would die, 10%+ would be hospitalised and our healthcare systems would fall apart. Prof Neil Ferguson from Imperial College London estimates it would take 2 years to reach a critical point of infection. Not good news if you are in a vulnerable group and need to self-isolate for two years! - Immunity. We aren’t sure yet if contracting COVID-19 make you immune. More worryingly, the virus might mutate or new viruses develop. - Long-Term Impact of COVID-19. We don’t know the long-term impact of contracting COVID-19. Perhaps nothing for many; but we know that COVID-19 goes beyond just infecting the lungs but can also impact other organs such as the kidney, liver and brain.

Another great visualisation from DanClark93 to share on how the price of oil futures has changed. But for the COVID-19 news, what’s happening to oil prices would be headlines for days/weeks. Ironically, COVID-19 has made what started as an oil price war into something even worse. The price of a barrel of West Texas Intermediate (WTI), the benchmark for US oil, has fallen as low as minus $37.63 a barrel. Basically, there is so much supply and such a reduced level of demand that there is nowhere to store oil. So oil firms have resorted to renting tankers to store the surplus supply and the cost of doing that has forced the price of US oil into negative territory. The markets are also signalling that the Opec+ output reduction deal will not be enough to balance supply with current demand. Don’t we want to use less oil? Pollution and global warming has abated as road transportation (50% of global consumption) and aviation industry (8%) have slumped. Good for the environment but it is also another negative impact to the world’s economy (and financial system). Distribution of oil demand in the OECD in 2017 by sector